ESSA Pharma to acquire Realm Therapeutics

ESSA Pharma (Nasdaq and TSX-V: EPI) has entered into a definitive agreement with Realm Therapeutics (Nasdaq: RLM) setting forth the terms of an acquisition whereby ESSA will acquire all of the issued and outstanding shares of Realm in an all-stock transaction.

The acquisition, subject inter alia to Realm Shareholder approval, is intended to be implemented by means of a UK Court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act 2006 and is expected to be completed by mid-year 2019.

Upon the closing of the acquisition, the company will continue to operate as ESSA Pharma trade on the Nasdaq Capital Market and TSX-V Market and operate in the USA as ESSA Pharmaceuticals Corp, a Houston, TX-registered wholly-owned subsidiary. The company will focus on advancing ESSA's pipeline of novel potential treatments for prostate and other cancers.